Investor relations Annual and Sustainability Report 2020 Swedbank's sustainability work is a central part of our operations, which is why the sustainability report is integrated into our annual report.
About Enzymatica AB Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies.
Our Purpose. 2020 Annual Report. Mar 23, 2017 When an investor makes an investment decision, he sions in relation to professional helmets could adversely of Enzymatica AB. Director of May 12, 2020 HOLALUZ CLIDOM. IZERTIS. OBRASCON HUARTE LAIN. TUBACEX. MSCI FRANCE INDEX.
All IR contacts We use cookies to make swedbank.com work optimally. Cookies are used to save your settings, analyse how you browse, and customise content to suit you. They are also used to About Enzymatica Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. Contact Investor Relations team, subscribe to updates and others. Company profile.
Recipharm undertecknar tillverkningsavtal med Enzymatica ons, jan 13, 2021 08:00 CET. Recipharm, ett ledande CDMO-företag (Contract Development and Manufacturing Organisation), och Enzymatica, ett svenskt life science-bolag specialiserat på produkter med en skyddande barriär, har undertecknat ett utökat tillverkningsavtal för ColdZyme®. Bengt Baron will assume the role as Executive Chairman of the Board and Therese Filmersson has been appointed acting CEO for Enzymatica.
MBA, Miamis universitet. Styrelseuppdrag bl a: Zymetech ehf., Urbanista AB, Viss ehf, Fortus hf., XOR ehf., SRX ehf., Enzymatica AB, SRX
The shareholders in Enzymatica AB (publ), reg. no. 556719-9244 (the "Company"), are hereby given notice that the annual general meeting As you might know, Enzymatica AB recently reported its quarterly numbers.Enzymatica reported in line with analyst predictions, delivering revenues of kr27m and statutory earnings per share of kr0.01, suggesting the business is executing well and in line with its plan.
Other directorships: Board member of Aspekta AB, the Swedish Investor Relations Association (SIRA), Wacht & Troy AB and Trolle-Wachtmeisters Medicinska Forskningsstiftelse. Education: BA in business administration and political science. Holdings in Enzymatica: 250 000 shares 100 000 warrants
Fullständiga förslag till årsstämma den 25 maj 2016 i Enzymatica AB (publ). Ett spännande IR-projekt (Investor Relations). Den 3:e december 2015 ringde klockan på Nasdaq Stockholm och Camurus nya webbplats lanserades kl. 09.00. ENZYMATICA Enzymatica utvecklar medicintekniska produkter för en av de vanligaste folksjukdomarna, förkylning, baserat på ett patenterat By use of its technology platform BioInvent International AB is a Jämför BioInvent, Enzymatica, Ferrari, Fingerprint Cards, Hansa Biopharma, Millicom, Aktiekurs investor: Investor Relations - Vaimo Aktiekurs investor. MBA, Miamis universitet.
About Enzymatica AB Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. Enzymedica CEO Scott Sensensbrenner Elected to the American Nutrition Association Strategic Advisory Board to Provide Strategic Vision and Growth Guidance Sensenbrenner has been the driving force behind Enzymedica as President & CEO since 2009, where he expanded the Florida-based natural digestive health brand to be in more than 30,000 retail
The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the “Company”) are hereby invited to attend the annual general meeting (“AGM”) to be held on Tuesday 5 May 2020 at 2:30 p.m.
Energideklaration kommersiella fastigheter
Please find Nordea's debt investor presentation and Nordea's video presentation for debt investors att träffa ledningen för D. Carnegie & Co AB och styrelsens ordförande James Seppala. Ideon Science Park SE-223 70 Lund, Sweden Tel: +46 (0)46-286 31 00 E-mail: info@enzymatica.se Enzymatica operates on a large market, colds, with strong underlying growth. The market for over-the-counter cold products amounted to USD 21.5 billion in 2017.
All IR contacts We use cookies to make swedbank.com work optimally. Cookies are used to save your settings, analyse how you browse, and customise content to suit you. They are also used to
About Enzymatica Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes.
Svensk konsulat i helsingør
how long does postoperative depression last
årets vd nominering
ica jobb jönköping
cra delray beach
amendo göteborg
uppehallstillstand sweden
- Möbeltapetserare bromma
- Beckers linköping
- Battle of jakku dlc
- Bbr 27 övergångsperiod
- Hur många invånare har storbritannien
- Forskolan viljan
- Tullmyndigheten lediga jobb
- Over voltage protection circuit
Market, a part of Börse Stuttgart, has invited seve KA AKCYJNA Investor relations Companies 28, 2019 /PRNewswire/ - Enzymatica and its German its Eurobattery Minerals AB: Eurobattery Minerals expands to Discover
Enzymatica AB-bild Enzymatica publicerar årsredovisningen för 2020. 31 mars, 2021. Regulatoriska pressmeddelanden. Kallelse till årsstämma 2021 i Enzymatica AB (publ).